| Autor: |
Eichelbaum, M., Spannbrucker, N., Dengler, H. |
| Zdroj: |
European Journal of Clinical Pharmacology; 1979, Vol. 16 Issue 3, p189-194, 6p |
| Abstrakt: |
Sparteine is metabolized by N-oxidation, which in some subjects is defective. The defect has a pronounced effect on the kinetics of the drug. In non-metabolisers elimination of sparteine proceeds entirely via renal excretion by a capacity-limited process, 99,9% of the dose being excreted as unchanged drug. In metabolisers the drug is mainly eliminated by metabolic degradation. Pronounced differences in β-phase half-life and total plasma clearance were observed between metabolisers (156 min; 535 ml · min) and nonmetabolisers (409 min; 180 ml · min). [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink